The TB-APEX data platform, hosted by ERA4TB partner, C-Path, aims to catalyze and accelerate TB research by curating and standardizing preclinical trial data and making this data available to qualified researchers.
As of January 2024, this platform is open for external researchers to apply for access to data held within it. Approved researchers can access patient-level data from at least sixty preclinical trials, and analyze this in aggregate, or filter and view individual subject-level data. There is currently no fee to access the data.
Currently the platform contains In Vitro and In Vivo data contributed by four organisations: Evotec, Baylor University, Johns Hopkins University (JHU), and Colorado State University (CSU). The platform includes data on demographic information, dose/concentration information, drug resistance information, biospecimen events, subject body weight, subject disposition, PK results and parameter, microbiological specimen results and study level information. Additional preclinical trial data is expected to be added in the future. All data is mapped to the Clinical Data Interchange Standards Consortium (CDISC) Standard for Exchange of Nonclinical Data (SEND).
How to register for access to the TB-APEX data platform?
Visit the C-Path Data Archive website to register for access. You must first review and agree to the Terms and Conditions for Use of the TB-APEX data platform. Once completed, researchers will be directed to the online application form.
How long will it take to process my access request?
The TB-PACTS access review committee will review all user access applications; this may take up to four weeks to process.
Further information
For more information on TB-APEX or how your organization can contribute data, please contact: codr_eu@c-path.eu
Acknowledgements
Creation of the TB-APEX data platform was made possible by a grant from the Bill & Melinda Gates Foundation.
Continued hosting and maintenance for the TB-APEX data platform is made possible by a grant from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853989. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, and in-kind support from EFPIA, Global Alliance for TB Drug Development, Bill & Melinda Gates Foundation and University of Dundee.
